The new laboratory space, located within the Human BioMolecular Research Institute, provides Regen with access to molecular and cellular biology facilities critical to its cancer stem cell research.
The company has already started experimental studies in the new laboratory with an initial focus on performing pre-clinical experiments whose objective is the advancement of its cancer stem cell and telomere therapeutic pipeline.
Regen chairman and CEO David Koos said: "This laboratory space provides us with the capacity to conduct in-house developmental and pre-clinical research with regards to our extensive product pipeline.
"Given that DifferonC, a gene-silencing based therapeutic for treatment of myelodysplastic syndrome, is our next planned IND, and we have three other downstream pipeline products, it has become important to possess our own laboratory capabilities to most seamlessly and effectively perform critical experiments internally prior to engaging a GLP facility."
Regen is focused on discovering undervalued regenerative medicine applications in the immunotherapy and stem cell space as well as rapidly advance these technologies through pre-clinical and Phase I/ II clinical trials.
The company is currently centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.